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The aim of this study was to compare NT-proBNP using the absolute values and NT-proBNP/ULN values that were standardized
by age and gender between three subgroups: those without ischemia (negative hs-troponin I and no anginal pain (hsTnI-/AP-)),
those with painless ischemia (hsTnI+/AP-), and those with painful ischemia (hsTnI+/AP+). Additionally, echocardiographic
parameters were compared in these three subgroups. The absolute value of NT-proBNP was significantly higher in the painful
ischemia subgroup (hsTnI-/AP- vs. hsTnI+/AP- vs. hsTnI+/AP+: 502 (174-833) vs. 969 (363-1346) vs. 2053 (323-3283) pg/ml;
p = 0 018 for the whole-model analysis). The standardized value of NT-proBNP/ULN was gradually increased (hsTnI-/AP- vs.
hsTnI+/AP- vs. hsTnI+/AP+: 3 61 + 0 63 vs. 6 90 + 1 31 vs. 9 35 + 1 87; p = 0 001 for the whole-model analysis). In the
comparison between subgroups (hsTnI-/AP- vs. hsTnI+/AP- vs. hsTnI+/AP+), two echocardiographic parameters increased
significantly. The left ventricular maximum wall thickness (LVMWT) at diastole was 1 99 ± 0 08 cm vs. 2 28 ± 0 13 cm vs.
2 49 ± 0 15 cm (p = 0 004 for the whole-model analysis). The maximal gradient of the provoked left ventricular outflow
tract (LVOT) gradient increased significantly in only the painful-ischemia subgroup (11 (7-30) mmHg vs. 12 (9.35-31.5)
mmHg vs. 100 (43-120) mmHg). In conclusion, both painless ischemia and painful ischemia are associated with a gradual,
significant increase in NT-proBNP/ULN in comparison to the double-negative hsTnI/AP subgroup. In contrast, NT-proBNP is
significantly higher in only the subgroup with painful ischemia.
1. Introduction
It is proposed [1, 2] that routine measurement biomarkers
especially including [1] both N-terminal pro-B-type NT-
pronatriuretic peptide (NT-proBNP) and cardiac troponin
(Tn) may be useful in the clinical evaluation and manage-
ment of patients with HCM. NT-proBNP is predominantly
secreted from the ventricles in response to increased myocyte
stretching from increased stress and pressure at the LV wall.
It is plausible that microvascular ischemia directly stimulates
the release of NT-proBNP in HCM. In clinical studies, there
is little information about the combined use of Tn and
plasma BNP as prognostic biomarkers for adverse events
mediated by myocardial ischemia with LV dysfunction [3].
In a study by Kubo et al. [3] on 167 patients with HCM,
TnI and BNP were measured only once at the initial exami-
nation without control measurements during a follow-up
period of more than 3 years (mean value). Patients with ele-
vated TnI values had more frequent adverse events. Similarly,
the risk of adverse events was higher in patients with high
BNP (≥200 pg/ml). Importantly, TnI used in combination
with BNP further improved the prognostic value, as patients
with high values of both cTnI and BNP had nearly 12 times
higher risk of cardiovascular events than patients with a
combination of low cTnI/BNP values. However, this study
had some important limitations because there was a long
time between the initial biomarker measurement and the
final event.
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In contrast, we studied the direct short-term relationship
between angina pectoris and the levels of both hsTnI and
NT-proBNP after a 24-hour monitoring period. Taking into
account methodological aspects, we compared NT-proBNP
using absolute values and NT-proBNP/ULN values that were
standardized by age and gender between three subgroups:
those without ischemia (negative hs-troponin I/no anginal
pain (hsTnI-/AP-)), those with painless ischemia (hsTnI
+/AP-), and those with painful ischemia (hsTnI+/AP+).
2. Methods
A total of 64 patients with HCM were recruited (mean age
37 ± 6 years, 33 men and 31 women). The study protocol
was approved by the local institutional review board (Komisja
Bioetyki Jagiellonian University KBET/119/B/2017). Informed
consent was obtained from each participant. All patients met
the standard diagnostic criteria for HCM [4]. In adults,
HCM is defined by a wall thickness ≥ 15mm in one or more
LV myocardial segments that is not explained solely by loading
conditions andmeasured by any imaging technique (echocardi-
ography (our method), cardiac magnetic resonance imaging
(CMR), or computed tomography (CT)) [4]. Patients on
current pharmacotherapy or without pharmacotherapy (newly
diagnosed patients referred to our ambulatory clinic) were
examined by echocardiography with LVOT gradient provoca-
tion by a combination of two natural stimuli (orthostatic test
and the Valsalva test).
The exclusion criteria were myocardial infarction with
ST-segment or non-ST-segment elevation (current or previ-
ous), previous alcohol septal ablation, significant coronary
stenosis in recent coronary angiography, diabetes mellitus,
regular sports activity, dilated LV cavity and decreased
LV contractibility (we included only patients with
LVEF > 50%), atrial fibrillation, and elevated serum creati-
nine levels resulting in eGFR < 60ml/min. We included only
patients with coronary microvessel disease, which is a
common abnormality in HCM at any age (inclusion criteria:
normal/near-normal coronary arteries or no indication of
coronary arteriography).
The minority of patients did not have coronary angiogra-
phy performed (young, without AP, without risk factors for
CAD—especially without diabetes mellitus—see below).
The risk for CAD was minimal and coronary angiography
was not indicated. Diabetes mellitus is usually linked with
silent ischemia from epicardial coronary arteries (so it is
necessary to exclude painless macrovascular stenosis).
Renal failure is a typical extracardiac factor related to TnI
elevation. Frequent sports activity may be responsible for
repetitive myocardial ischemia in some patients [5]. Patients
were asked to report presence or absence of angina pec-
toris episodes before the 24-hour period. Next, an echocar-
diographic examination was performed. Just after, hsTnI
and NT-proBNP (absolute or upper limit of normal
(ULN)) were measured. There were 38 patients in sub-
group 0 (i.e., the double-negative group; hsTnI-/AP-). Sub-
group 1 (hsTnI+/AP-) was composed of 12 patients, and
subgroup 2 (double positive) consisted of 14 patients. A
cut-off value of 19 ng/l was used according to the manufac-
turer’s instructions (bioMerieux VIDAS® High sensitive
Troponin I). This value represents the 99th percentile of a
presumably healthy population.
High-sensitivity troponin tests were performed with the
use of the VIDAS High sensitive Troponin I (TNHS). The
test is capable of measuring cardiac troponin I concentration
in the range of 4.9-40,000.00 pg/ml (ng/1) without the need
for dilution. The TNHS test was designed to meet the follow-
ing criteria of repeatability and intralaboratory precision
(Table 1).
The NT-proBNP tests were performed with use of an
Elecsys proBNP II Cobas e601 system. The test is capable of
measuring the NT-proBNP concentration in the range of
5–35,000 pg/ml without the need for dilution.
The proBNP II test was designed to meet the following cri-
teria of repeatability and intralaboratory precision (Table 2).
The NT-proBNP levels were presented as absolute values
and transformed values that were standardized according to
sex and age based on the manufacturer’s guidelines. (http://
www.rochecanada.com/content/dam/roche_canada/en_CA/
documents/package_inserts/ProBNPII-04842464190-EN-V9-
CAN.pdf). Values NT-proBNP greater than the 95th percen-
tile for age and gender (the ULN) were considered abnormal.
Therefore, the results were expressed as the ratio of the
NT-proBNP to age and sex-matched ULN. Ratios > 1 0 were
considered abnormal [6]. This standardization of NT-
proBNP provides a normal distribution of data, whereas
absolute values were distributed abnormally. In this situa-
tion, we do not need to perform a logarithmic transformation
for artificial calculation.
For the statistical analysis, continuous variables were
presented as the mean (±standard deviation (SD)) or median
(interquartile range (IQR)). NT-proBNP levels were
Table 1: TNHS test repeatability and intralaboratory precision.
High-sensitivity troponin
(pg/ml; ng/l)
Assay output requirements
Repeatability
(within the same
series) (CV (%))
Intralaboratory
precision (total)
(CV (%))
9-20 ≤10% ≤12%
>20 ≤10% ≤10%
Precision was assessed in accordance with the EP05-A3 protocol of the
Clinical and Laboratory Standards Institute (CLSI): “Evaluation of Precision
of Quantitative Measurement Procedures; Approved Guidelines—Third
Edition” (CLSI Document EP05-A3).
Table 2: NT-proBNP test repeatability and intralaboratory precision.
NT-proBNP Assay output requirements
pg/ml pmol/l
Repeatability
(within the same
series) (CV (%))
Intralaboratory
precision (total)
(CV (%))
100-500 11.8–59.0 ≤5% ≤8%
>500 >59,0 ≤7% ≤10%
Precision was assessed in accordance with the EP05-A3 protocol of the
Clinical and Laboratory Standards Institute (CLSI): “Evaluation of Precision
of Quantitative Measurement Procedures; Approved Guidelines—Third
Edition” (CLSI Document EP05-A3).
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compared between the three subgroups of patients using the
Kruskal–Wallis test, which was also used to compare the
maximal LVOT gradient. The values of standardized NT-
proBNP/ULN had a normal distribution according to the
Kolmogorov-Smirnov test and were compared using
ANOVA for comparison, which was also used to compare
the LV maximum wall thickness (LVMWT) and left atrial
diameter (LAD). Stepwise multiple linear regression analysis
was used to identify factors independently correlated with
NT-proBNP levels. Patients’ age, gender, troponin level, pres-
ence of angina, and several echocardiographic parameters
(max LVH, resting LVOT gradient, maximal LVOT gradient,
and LAD) were tested as possible candidates. A p value of
<0.05 was considered statistically significant (Statistica 12.0).
3. Results
Demographics, relevant echocardiographic information,
medical history, and treatment data are presented in Table 3.
Among all patients, chest pain was present more than
10 hours (during daily physical activity on the first day)
before the blood sampling at 8.00 a.m. on the second
day in the morning. There were no chest pains during
the night.
The absolute value of NT-proBNP was significantly
higher in the painful ischemia subgroup (hsTnI-/AP- vs.
hsTnI+/AP- vs. hsTnI+/AP+: 502 (174-833) vs. 969 (363-
1346) vs. 2053 (323-3283) pg/ml; p = 0 0178 for the whole
model, Figure 1).
Table 3: The baseline characteristics of HCM patients.
(a)
Mean age 37 ± 6 years
Males/females 33/31
The ICD implantation 8 patients
EF % 59 ± 8%
hsTnI value 73 74 ± 232 9
Medications Patients
Beta-blockers 43
Verapamil 17
Diuretics 3
ACE inhibitors 4
Past history of AP in years 4 1 + 1 2 years
(b)
Total (N = 64) Subgroup 0 (N = 38) Subgroup 1 (N = 12) Subgroup 2 (N = 14)
Baseline characteristics of subgroups of patients with HCM
NYHA
Class I (n (%)) 12 (19%) 9 (24%) 3 (25%) 0∗ ,∗∗
Class II (n (%)) 33 (51%) 20 (52%) 6 (50%) 7 (50%)
Class III (n (%)) 19 (30%) 9 (24%) 3 (25%) 7 (50%)∗
CCS
Class I (n (%)) 24 (38%) 18 (47%) 5 (42%) 1 (7%)∗ ,∗∗
Class II (n (%)) 29 (45%) 16 (42%) 5 (42%) 8 (57%)
Class III (n (%)) 11 (17%) 4 (11%) 2 (8%) 5 (36%)∗
Syncope (n (%)) 25 (39%) 13 (34%) 5 (42%) 7 (50%)
Sudden death in family history
(n (%))
23 (36%) 14 (37%) 4 (33%) 5 (36%)
All patients had Holter
NSVT in Holter (n (%)) 26 (41%) 15 (39%) 5 (42%) 6 (43%)
LV maximal wall thickness
(LVMWT) at diastole (cm)
2 23 ± 0 57 Detailed calculation in Figure 3
Resting LVOT gradient, ≥30
mmHg (n (%))
14 (22%) 6 (16%) 3 (25%) 5 (36%)
Provocable LVOT gradient,
≥30 mmHg (n (%)) 14 (22%) 5 (13%) 3 (25%)
6 (43%)∗
Left atrial diameter (cm) 4 78 ± 0 64 Detailed calculation in Figure 5
Abbreviations: CCS: Canadian Cardiovascular Society; LVOT: left ventricular outflow tract; LV: left ventricular; NSVT: nonsustained ventricular tachycardia;
NYHA: New York Heart Association. ∗p < 0 05 subgroup 0 vs. 2; ∗∗p < 0 05 subgroup 1 vs. 2.
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The standardized value of NT-proBNP/ULN showed a
gradual significant increase (hsTnI-/AP- vs. hsTnI+/AP- vs.
hsTnI+/AP+: 3 59 + 0 63 vs. 6 90 + 1 31 vs. 9 35 + 1 87; p =
0 001 for the whole model in ANOVA; Figure 2).
In the comparison between subgroups (hsTnI-/AP- vs.
hsTnI+/AP- vs. hsTnI+/AP+), two echocardiographic
parameters increased significantly. The LV maximum wall
thickness (LVMWT) at diastole was 1 99 ± 0 08 cm vs.
2 28 ± 0 13 cm vs. 2 49 ± 0 15 cm (Figure 3, normal distri-
bution, ANOVA test, p = 0 004 in the whole-model analysis).
The maximal provoked LVOT gradient increased
significantly in only the painful-ischemia subgroup: 11
(7-30) mmHg vs. 12 (9.35-31.5) mmHg vs. 100 (43-120)
mmHg (Figure 4; abnormal distribution: Kruskal–Wallis
test, p < 0 001 for the whole model).
The increase of LAD from subgroup to subgroup was
nonstatistically significant (4 28 ± 0 16 vs. 4 64 ± 0 28 vs.
4 95 ± 0 15; p = 0 051 for the whole model, Figure 5).
NT-proBNP/ULN was more strongly correlated with
echocardiographic parameters than NT-proBNP (Table 4).
In multiple linear regression analysis, resting LVOT gra-
dient, LAD, and the presence of angina were identified as
independent factors affecting NT-proBNP levels in patients
with HCM (Table 5).
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Figure 1: Comparison of NT-proBNP between subgroup 0 (hsTnI-/AP-), subgroup 1 (hsTnI+/AP-), and subgroup 2 (hsTnI+/AP+);
p = 0 018 for the whole model. For inter-subgroup comparison: ∗subgroup 0 vs. 1: p = 1 000; ∗∗subgroup 1 vs. 2: p = 0 177; ∗∗∗subgroup 0
vs. 2: p = 0 004.
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Figure 2: Comparison of NT-proBNP standardized according to age and sex between subgroup 0 (hsTnI-/AP-), subgroup 1 (hsTnI+/AP-),
and subgroup 2 (hsTnI+/AP+). p = 0 001 for the whole model. Inter-subgroup comparison: ∗subgroup 0 vs. 1: p = 0 049; ∗∗subgroup 1 vs. 2:
p = 0 208; ∗∗∗subgroup 0 vs. 2: p < 0 001.
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Figure 3: Significant increase (p = 0 004) of LVMWT in the whole model. Inter-subgroup comparison: ∗subgroup 0 vs.1: p = 0 083;
∗∗subgroup 1 vs. 2: p = 0 256; ∗∗∗subgroup 0 vs. 2: p = 0 001.
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Figure 4: Significant increase (p < 0 001 for the whole model) of provocable LVOT gradient. Inter-subgroup comparison: ∗subgroup 0 vs. 1:
p = 1 000; ∗∗subgroup 1 vs. 2: p < 0 001; ∗∗∗subgroup 0 vs. 2: p = 0 007.
5Disease Markers
4. Discussion
hsTnI is a precise and very useful biomarker for the detection
of even small, focal, subendocardial myocardial injury caused
by ischemia in patients with HCM. In recent investigations,
measurements of hsTnI levels were synchronized with a non-
invasive assessment of clinical and hemodynamic parameters
within a short time, similar with previous studies [7–11]. We
have documented that levels of both NT-proBNP and
NT-proBNP/ULN were the highest in the most ischemic
subgroup (painful angina pectoris; hsTnI+/AP+). Both
biomarkers and echocardiographic parameters have not
been investigated previously using currently proposed
models of analysis [12–15].
In the hsTnI+/AP+ subgroup, both LVMWT at diastole
and the provocable LVOT gradient had significantly higher
values. In the subgroup of painless ischemia, the LVMWT
at diastole had an intermediate value and differed signifi-
cantly from the values of the nonischemic and painful ische-
mic subgroups (Figure 3). Our findings are rational because
both increased myocardial mass and LVOT gradient induce
myocardial ischemia through an increase in oxygen demand.
LAD is the third echocardiographic risk factor for sudden
death included in the guideline calculator from the European
Society of Cardiology [4, 10, 11]. This value was increased in
subgroups, but the differences were only on the statistical
borderline (p = 0 052, Figure 5).
In an experimental protocol for HCM with more physio-
logical conditions [15], biomarkers were measured before
exercise testing with only one control point at 4 hours post-
exercise. NT-proBNP increased by 27% after exercise. Simi-
larly, hsTnI increased by 24% 4hours after exercise, but the
differences were not statistically significant. The 4-hour
check-point in the postexercise recovery seems to be too long
for peak NT-proBNP and too short for peak hsTnI values. In
small study with 7 young HCM patients without symptom-
atic coronary artery disease, authors [16] detected elevated
troponin levels after physical exercise in 5 patients. In serial
measurement, the peak concentration had been reached
between 6 and 9 hours and levels returned to preexercise
values within 24 hours. Troponin release was consistently
diminished after use of a beta-blocker. We tried to study this
problem by using a 24-hour spectrum of time and with a
more physiological approach. We monitored the 24-hour
physical activity and occurrence of angina. It has been
proposed that moderate, fluctuating exercise during daily
physical activity may be more appropriate to detect abnor-
malities in cardiac biomarker release, rather than maximum
symptom-limited exercise [15]. To support the theory about
the link with postexercise prolonged myocardial ischemia,
we need a larger study, with many points in time to mea-
sure hsTnI (24-hour profile of release). Tesic et al. [17]
recently found that the coronary flow reserve in the left
anterior descending artery appeared to be an independent
predictor of NT-proBNP. Thus, elevated NT-proBNP might
be the result of cardiac ischemia indicated by low coronary
flow reserve.
4.1. Limitations. The main limitation of study is the relatively
small number of patients due to several exclusion criteria.
Not all of the patients underwent coronary arteriograms,
which was only performed on patients with the appropriate
indications. The minority of patients did not have coronary
angiography performed (young, without AP, and without
p = 0.051 for whole model
Vertical bars denote ± standard errors
0 1 2
hs-troponin (status)/angina pectoris (status)
4.0
4.2
4.4
4.6
4.8
5.0
5.2
5.4
LA
D
 (c
m
)
p = 0.226⁎ p = 0.379⁎⁎⁎
p = 0.017⁎⁎⁎
Figure 5: There was a nonsignificant increase in LAD (p = 0 051 for the whole model). ∗Subgroup 0 vs. 1: p = 0 226; ∗∗subgroup 1 vs. 2:
p = 0 379; ∗∗∗subgroup 0 vs. 2: p = 0 017.
Table 4: Correlations between NT-proBNP(/ULN) and
echocardiographic parameters.
NT-proBNP NT-proBNP/ULN
LVMWT r = 0 24∗ r = 0 36
LVOTG max r = 0 44 r = 0 54
LAD r = 0 41 r = 0 42
∗Nonsignificant; remaining correlations were significant; p < 0 05.
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risk factors for CAD). The risk for CAD was minimal and
coronary angiography was not indicated. The strategy of
noninvasive identification of subgroups with low likelihood
of obstructive CAD [18] is effective.
The next limitation of the study was the following
problem. We measured biomarkers simultaneously, once in
time, and we do not have a sufficient period of follow-up with
prognostic findings.
5. Conclusions
Both painless ischemia and painful ischemia are associated
with a gradual, significant increase in NT-proBNP/ULN in
comparison to the double-negative hsTnI/AP subgroup. In
contrast, NT-proBNP was significantly higher in only the
subgroup with painful ischemia. In the comparison between
subgroups (hsTnI-/AP- vs. hsTnI+/AP- vs. hsTnI+/AP+),
two echocardiographic parameters increased significantly:
LVMWT at diastole (in the whole-model analysis) and the
maximal provoked LVO T gradient (only in the painful
subgroup in both analysis models).
Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request.
Additional Points
Clinical Perspective. The study documented the evidence that
positive troponin status is timely related with higher bio-
marker value NT-proBNP reflecting LV myocardial dysfunc-
tion. From the clinical perspective, monitoring of these 2
biomarkers may improve pharmacological and nonpharma-
cological treatments and safety of exercise training.
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